WO2005021504A2 - New crystalline forms of carvedilol - Google Patents

New crystalline forms of carvedilol Download PDF

Info

Publication number
WO2005021504A2
WO2005021504A2 PCT/SI2004/000029 SI2004000029W WO2005021504A2 WO 2005021504 A2 WO2005021504 A2 WO 2005021504A2 SI 2004000029 W SI2004000029 W SI 2004000029W WO 2005021504 A2 WO2005021504 A2 WO 2005021504A2
Authority
WO
WIPO (PCT)
Prior art keywords
carvedilol
crystalline carvedilol
ethyl acetate
carvedilol form
crystalline
Prior art date
Application number
PCT/SI2004/000029
Other languages
French (fr)
Other versions
WO2005021504A3 (en
Inventor
Rok Zupet
Marija Grcman
Matej Smrkolj
Original Assignee
Krka, Tovarna Zdravil, D.D., Novo Mesto
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Krka, Tovarna Zdravil, D.D., Novo Mesto filed Critical Krka, Tovarna Zdravil, D.D., Novo Mesto
Priority to EP04775682A priority Critical patent/EP1660451A2/en
Publication of WO2005021504A2 publication Critical patent/WO2005021504A2/en
Publication of WO2005021504A3 publication Critical patent/WO2005021504A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system

Definitions

  • the invention relates to the field of physical and synthetic organic chemistry. It relates to the process for crystallization of novel solid crystalline modification of carvedilol or solvate thereof, having an excellent efficacy as pharmaceuticals.
  • Carvedilol ( ⁇ )- 1 -(9H-carbazolyl-4-oxy)-3-[[2-(2-methoxyphenoxy) ethyl]amino]-2-propanol, is a non selective ⁇ -adrenergic blocker with ⁇ l-blocking activity.
  • Solid drug formulations are useful in the treatment of hypertension, congestive heart failure and angina. It is used in pharmaceutical compositions as a racemic mixture of both enantiomers, having structural formula:
  • Carvedilol possesses lively polymorphic behaviour. Depending to the method of isolation, several different solid crystalline modifications are identified. Several stable modifications and some stable and semi stable hydrates, solvates and salts of the drug were discovered and characterized by many development groups. The solid polymorphs, pseudo polymorphs, hydrates, solvates and salts are well analytically characterized. Materials could be successfully distinguished comparing their IR, Raman, XRPD, DSC or solid NMR spectra and melting points.
  • EP 0 893 440 Al discloses the crystallization of carvedilol from methanol. Thermodynamically more stable modification I was isolated.
  • WO 02/00216 and WO 03/005970 describe stable modification HI of carvedilol. According to the experiments disclosed in the cited applications, polymorph HI could be prepared by crystallization from water or precipitation from organic solvent by addition of water used as anti-solvent.
  • WO 02/00216 describes also new solid modifications of carvedilol, designated as forms IV and V, which could be prepared by isolation from organic solvents with precipitation by addition of cyclohexane or hexane.
  • WO 03/029214 Al describes new modification of carvedilol, which is hemihydrate and prepared by dissolving spray congealed material in water or methanol/water as crystallization media.
  • WO 03/059807 A2 describes a crystalline solid of carvedilol solvate, designated as form VI.
  • Figure 1 FT-IR spectrum of crystalline form VII.
  • Figure 2 DSC curve of crystalline form VH.
  • Figure 3 XRPD pattern of crystalline form VII.
  • Figure 4 FT-IR spectrum of crystalline form LX.
  • Figure 5 DSC curve of crystalline form IX.
  • Figure 6 XRPD pattern of crystalline form LX.
  • DSC scans were recorded on Perkin Elmer DSC 7 Scanning calorimeter. Samples of approx. 3 mg were scanned between 30 and 130°C at heating rate of 10°C/min under nitrogen atmosphere in aluminium DSC open pans.
  • X-ray powder diffraction patterns were obtained by Phillips PW3040/60 X'Pert PRO diffractometer equipped by X'Celerator detector; CuK ⁇ radiation 1,541874A. The 2 ⁇ range was 4-30°, and step size was 0,0167°. Detailed description of the invention
  • a process for the preparation of crystalline carvedilol is performed in ethyl acetate as a crystallization solvent or ethyl acetate with added water in miscible mixtures, as a crystallization solvent.
  • the present invention further provides processes for crystallization, comprising dissolving carvedilol in concentrations from 1-40% w/w in heated solvents, as ethyl acetate or ethyl acetate/water mixtures, and cooling the crystallization mixtures to lower temperatures than the boiling point of the crystallization mixtures to provoke crystallization of carvedilol solid crystalline modifications.
  • Carvedilol could be successfully crystallized from ethyl acetate using the difference in solubility of the drug, which is higher in warm or boiling ethyl acetate and lower in cooled ethyl acetate, where at the temperature lower than 0°C, the solubility of carvedilol is lower than 0.5% w/w.
  • Crystallization of solid crystalline drug from solutions containing 25-30% w/w of carvedilol starts at temperatures higher than 60°C.
  • Crystallization of solid crystalline drug from solutions containing 2-10% w/w of carvedilol starts at temperatures from 20-40°C.
  • Carvedilol prepared by crystallization from 2% w/w carvedilol ethyl acetate solution contains
  • the solvated form is well stable in suspension, and as well could be isolated and characterized. At ambient temperature it is only temporarily stable and in a week time it re crystallizes to more stable solid modifications.
  • meta-stable solvated form is transformed to modification ⁇ , HI or to a mixture of both modifications.
  • the present invention further provides the novel crystalline solid modification of carvedilol, non-solvated form, designated as form VH.
  • the non-solvated crystalline form VII is characterized by the melting point 68.8-72.4°C.
  • the form VII exhibits IR spectrum, Figure 1, with characteristic absorption bands at: 3469.2 cm “1 , 3393.5 cm “1 , 3345.5 cm “1 , 3278.1 cm “1 , 3054.5 cm “1 , 3009.0 cm “1 , 2909.8 cm “1 , 2871.2 cm “1 , 2836.5 cm “1 , 1736.2 cm “1 , 1625.8 cm “1 , 1606.3 cm “1 , 1589.1 cm “1 , 1507.6 cm '1 , 1452.7 cm “1 , 1441.4 cm “1 , 1383.1 cm “1 , 1347.5 cm “1 , 1332.7 cm “1 , 1305.0 cm “1 , 1284.5 cm “1 , 1255.6 cm “1 , 1226.9 cm “1 , 1215.0 cm “1 , 1178.8 cm “1 , 1151.6 cm “1 , 1123.6 cm “1 , 1095.8 cm “1 , 1040.0 cm “1
  • the most characteristic absorption bands of the form VII are at: 3469.2 cm “1 , 3278.1 cm '1 , 2871.2 cm “1 , 1123.6 cm “1 , 1095.8 cm “1 , 745.0 cm “1 , 722.9 cm “1 .
  • the form VII is further characterized by DSC analysis, Figure 2.
  • the DSC curve shows two endotherms; the first endotherm with the peak temperature at about 73°C and the second one with the peak temperature at about 114°C.
  • the first endotherm is due to the polymo ⁇ hic transition from form VII to more stable form II, the second endotherm is the melting of form ⁇ .
  • the crystalline form VII is further identified by XRPD analysis, Figure 3.
  • the X-ray powder diffraction pattern of the form VII shows characteristic two-theta values at: 6.42, 6.78, 10.94, 11.58, 12.90, 13.62, 16.79, 17.51, 17.90, 18.81, 19.42, 20.83, 21.19, 21.93, 23.30, 24.49, 25.27, 26.09, 27.20, 29.21 ⁇ 0.1.
  • the most characteristic diffractions of the form VEt are at: 6.42, 6.78, 10.94, 11.58, 12.90, 13.62, 16.79, 17.51, 17.90, 23.30 and 27.20 ⁇ 0.1 two-theta degrees.
  • modification II is isolated in pure crystalline mo ⁇ hological form.
  • modification IQ in pure form or in mixtures with modification II is formed.
  • the mixtures of modification HI and new polymo ⁇ hic modification LX could be isolated using ethyl acetate with 2-3% w/w of water for re crystallization of carvedilol.
  • the pure new polymo ⁇ hic modification LX of carvedilol is prepared using ethyl acetate and water in a miscible mixture as a solvent for crystallization.
  • the miscible mixture of ethyl acetate and water contains preferably more than 3% w/w of water and most preferably more than 4% w/w of water.
  • the preferred concentration of carvedilol is from 8-25% w/w.
  • the present invention further provides the novel crystalline solid modification of carvedilol, designated as form LX.
  • the form LX is characterized by the melting point 94.5-96.2°C.
  • the form LX exhibits IR spectrum, Figure 4, with characteristic abso ⁇ tion bands at: 3568.0 cm “1 , 3339.1 cm “1 , 3287.9 cm “1 , 3201.4 cm “1 , 3052.8 cm 2976.3 cm “1 , 2942.9 cm
  • the form LX is further characterized also by DSC analysis.
  • the DSC curve of form LX ( Figure 5), exhibits the minor endotherm at the peak temperature of about 80°C and the major endotherm at the peak temperature of about 99°C and the onset temperature of about 95°C.
  • the semi hydrated modification LX releases water from the crystal lattice at temperatures higher than 60°C (the first endotherm exhibits from DSC curve), and there formed non- hydrated modification, which is characterized by the second DSC endotherm. Up to the melting point the non-hydrated material retains the same crystalline lattice. Exposing the non- hydrated modification to the normal ambient environment and temperatures lower than 60°C, reversible hydratation of the anhydrous form occurs and the semi hydrated modification is obtained.
  • the form LX is also analyzed by XRPD analysis, Figure 6.
  • the X-ray powder diffraction pattern of the form IX shows characteristic two-theta values at: 6.16, 6.46, 8.39, 10.88, 11.39, 12.35, 12.98, 13.62, 14.72, 16.86, 17.42, 18.26, 19.28, 19.58, 21.88, 23.15, 24.61, 25.58, 26.06, 27.40, 27.63, 29.01, 29.55 ⁇ 0.1.
  • the most characteristic diffractions of the form LX are at 6.16, 6.46, 11.39, 12.35, 13.62, 14.72, 16.86, 19.28, 19.58 and 23.15 ⁇ 0.1 two-theta degrees.
  • Carvedilol ethyl acetate solvate was dried at reduced pressure 10-20 mmHg at maximum 50°C to evaporate the solvent and after loss of weight for 12 tol5% in 6-8 hours, non- solvated carvedilol of mo ⁇ hological form VH with the melting point 68.8-72.4°C was isolated.
  • Crystalline carvedilol form II was obtained by drying carvedilol form VII at temperature 70- 80°C for 6-8 hours.
  • Example 4

Abstract

The present invention relates to new crystalline carvedilol forms VII and IX and to processes for the preparation thereof. Particularly, this invention relates to processes of the isolation of carvedilol, using ethyl acetate as a solvent.

Description

J EW CRYSTALLINE FORMS OF CARVEDILOL
Field of the invention
The invention relates to the field of physical and synthetic organic chemistry. It relates to the process for crystallization of novel solid crystalline modification of carvedilol or solvate thereof, having an excellent efficacy as pharmaceuticals.
Background of the invention
Carvedilol, (±)- 1 -(9H-carbazolyl-4-oxy)-3-[[2-(2-methoxyphenoxy) ethyl]amino]-2-propanol, is a non selective β-adrenergic blocker with αl-blocking activity. Solid drug formulations are useful in the treatment of hypertension, congestive heart failure and angina. It is used in pharmaceutical compositions as a racemic mixture of both enantiomers, having structural formula:
Figure imgf000002_0001
Carvedilol possesses colourful polymorphic behaviour. Depending to the method of isolation, several different solid crystalline modifications are identified. Several stable modifications and some stable and semi stable hydrates, solvates and salts of the drug were discovered and characterized by many development groups. The solid polymorphs, pseudo polymorphs, hydrates, solvates and salts are well analytically characterized. Materials could be successfully distinguished comparing their IR, Raman, XRPD, DSC or solid NMR spectra and melting points.
The synthesis of carvedilol is consisted from several consecutive synthetic steps. The stable solid form, used for oral pharmaceutical formulations, is isolated from ethyl acetate. The methods for the synthesis and isolation are disclosed in EP 0004920 Bl. EP 0 004 920 Bl discloses the isolation of carvedilol from ethyl acetate. Following the procedure, pure and stable modification π of carvedilol is isolated and characterized by melting point.
EP 0 893 440 Al discloses the crystallization of carvedilol from methanol. Thermodynamically more stable modification I was isolated.
WO 02/00216 and WO 03/005970 describe stable modification HI of carvedilol. According to the experiments disclosed in the cited applications, polymorph HI could be prepared by crystallization from water or precipitation from organic solvent by addition of water used as anti-solvent.
WO 02/00216 describes also new solid modifications of carvedilol, designated as forms IV and V, which could be prepared by isolation from organic solvents with precipitation by addition of cyclohexane or hexane.
WO 03/029214 Al describes new modification of carvedilol, which is hemihydrate and prepared by dissolving spray congealed material in water or methanol/water as crystallization media.
WO 03/059807 A2 describes a crystalline solid of carvedilol solvate, designated as form VI.
Technical problem
Appearance of organic compounds in different solid modifications is a challenging topic in pharmaceutical industry. The synthetic processes used for production, especially the isolation steps and industrial pharmaceutical processes are highly investigated. Qualitative and quantitative physical parameters of particular technological steps are elaborated and validated.
Different solid modifications of the same compound usually exhibit different properties in dissolution and bulk properties which have a significant effect to method of formulation of the solid drug and finally could effect the drug bioavailability. The active pharmaceutical ingredients isolated in processes for the synthesis and used in formulations are to be in defined crystalline modifications, and usually with validated bulk properties, like particle size or specific surface.
Summary of the invention
In our investigation of the isolating step for the preparation of carvedilol, using ethyl acetate as a solvent, surprisingly new crystalline carvedilol forms were found. We isolated different solid crystalline modifications of carvedilol in the way that we modified concentration of the drug in ethyl acetate solution and water concentration in ethyl acetate in which the drug is dissolved and crystallized.
Brief description of the figures
Figure 1: FT-IR spectrum of crystalline form VII. Figure 2: DSC curve of crystalline form VH. Figure 3: XRPD pattern of crystalline form VII. Figure 4: FT-IR spectrum of crystalline form LX. Figure 5: DSC curve of crystalline form IX. Figure 6: XRPD pattern of crystalline form LX.
Methods of the measurement
FT-IR spectra in KBr pellets were recorded over the wave number range of 4000-400cm"1 with a Paragon 1000 Perkin Elmer Spectrometer at resolution 4 cm"1.
DSC scans were recorded on Perkin Elmer DSC 7 Scanning calorimeter. Samples of approx. 3 mg were scanned between 30 and 130°C at heating rate of 10°C/min under nitrogen atmosphere in aluminium DSC open pans.
X-ray powder diffraction patterns were obtained by Phillips PW3040/60 X'Pert PRO diffractometer equipped by X'Celerator detector; CuKα radiation 1,541874A. The 2Θ range was 4-30°, and step size was 0,0167°. Detailed description of the invention
According to the present invention, a process for the preparation of crystalline carvedilol is performed in ethyl acetate as a crystallization solvent or ethyl acetate with added water in miscible mixtures, as a crystallization solvent.
The present invention further provides processes for crystallization, comprising dissolving carvedilol in concentrations from 1-40% w/w in heated solvents, as ethyl acetate or ethyl acetate/water mixtures, and cooling the crystallization mixtures to lower temperatures than the boiling point of the crystallization mixtures to provoke crystallization of carvedilol solid crystalline modifications.
Carvedilol could be successfully crystallized from ethyl acetate using the difference in solubility of the drug, which is higher in warm or boiling ethyl acetate and lower in cooled ethyl acetate, where at the temperature lower than 0°C, the solubility of carvedilol is lower than 0.5% w/w.
With cooling the clear carvedilol solutions in ethyl acetate to lower temperatures than the boiling point of ethyl acetate we can observe crystallization of solid material.
Crystallization of solid crystalline drug from solutions containing 25-30% w/w of carvedilol starts at temperatures higher than 60°C.
Crystallization of solid crystalline drug from solutions containing 2-10% w/w of carvedilol starts at temperatures from 20-40°C.
Crystallization of solid crystalline drug from solutions with concentrations from 10-25% w/w evidently occurs in temperature interval from 40-60°C.
If we are using the carvedilol preparation method with crystallization of the drug from solutions containing 3-30% w/w of carvedilol in ethyl acetate, pure carvedilol modification π is formed and isolated, however in some particular conditions appearance of carvedilol solvates could be detected.
By lowering the concentration of carvedilol in ethyl acetate the occurrence of ethyl acetate solvates of carvedilol is more probable. By crystallization of carvedilol from ethyl acetate solutions in ethyl acetate at concentrations lower than 10% w/w, preferably 5% w/w and most preferably 3% w/w, the formation of carvedilol solvates is predominant.
Carvedilol prepared by crystallization from 2% w/w carvedilol ethyl acetate solution contains
12% w/w of included ethyl acetate in the crystal lattice of solid material.
The solvated form is well stable in suspension, and as well could be isolated and characterized. At ambient temperature it is only temporarily stable and in a week time it re crystallizes to more stable solid modifications.
Using the drying temperature higher than 50°C, preferably 55°C and most preferably 60°C during the drying process, at normal or reduced pressure applied, meta-stable solvated form is transformed to modification π, HI or to a mixture of both modifications.
Applying vacuum drying of ethyl acetate solvates at temperatures lower than 50°C, also non- solvated carvedilol modification VII could be isolated. The modification is stable at the temperatures lower than 50°C, however it re crystallizes in solid form to more stable modification II or to the mixture of modifications II and HI at higher temperatures and/or at longer storage times.
Applying drying of ethyl acetate solvates or crystalline carvedilol form VII at temperatures from 60-100X a stable modification H could be isolated. The preferred temperature range is
70-80°C.
The present invention further provides the novel crystalline solid modification of carvedilol, non-solvated form, designated as form VH.
The non-solvated crystalline form VII is characterized by the melting point 68.8-72.4°C.
The form VII exhibits IR spectrum, Figure 1, with characteristic absorption bands at: 3469.2 cm"1, 3393.5 cm"1, 3345.5 cm"1, 3278.1 cm"1, 3054.5 cm"1, 3009.0 cm"1, 2909.8 cm"1, 2871.2 cm"1, 2836.5 cm"1, 1736.2 cm"1, 1625.8 cm"1, 1606.3 cm"1, 1589.1 cm"1, 1507.6 cm'1, 1452.7 cm"1, 1441.4 cm"1, 1383.1 cm"1, 1347.5 cm"1, 1332.7 cm"1, 1305.0 cm"1, 1284.5 cm"1, 1255.6 cm"1, 1226.9 cm"1, 1215.0 cm"1, 1178.8 cm"1, 1151.6 cm"1, 1123.6 cm"1, 1095.8 cm"1, 1040.0 cm"1, 1020.9 cm"1, 992.6 cm"1, 957.1 cm"1, 938.4 cm"1, 907.0 cm"1, 848.1 cm"1, 798.1 cm"1, 784.1 cm"1, 745.0 cm"1, 722.9 cm"1, 621.6 cm"1, 611.4 cm"1, 575.9 cm"1 , 538.4 cm"1 , 483.0 cm"1 , 434.1 cm"1. The most characteristic absorption bands of the form VII are at: 3469.2 cm"1, 3278.1 cm'1, 2871.2 cm"1, 1123.6 cm"1, 1095.8 cm"1, 745.0 cm"1, 722.9 cm"1.
The form VII is further characterized by DSC analysis, Figure 2. The DSC curve shows two endotherms; the first endotherm with the peak temperature at about 73°C and the second one with the peak temperature at about 114°C. The first endotherm is due to the polymoφhic transition from form VII to more stable form II, the second endotherm is the melting of form π.
The crystalline form VII is further identified by XRPD analysis, Figure 3. The X-ray powder diffraction pattern of the form VII shows characteristic two-theta values at: 6.42, 6.78, 10.94, 11.58, 12.90, 13.62, 16.79, 17.51, 17.90, 18.81, 19.42, 20.83, 21.19, 21.93, 23.30, 24.49, 25.27, 26.09, 27.20, 29.21 ±0.1.
The most characteristic diffractions of the form VEt are at: 6.42, 6.78, 10.94, 11.58, 12.90, 13.62, 16.79, 17.51, 17.90, 23.30 and 27.20 ± 0.1 two-theta degrees.
Our further investigation was the usage of the mixtures of ethyl acetate and water as a solvent system for re crystallization of carvedilol. Some additional interesting morphological behaviour of carvedilol was observed.
Generally, if we are using miscible solutions of ethyl acetate and water for crystallization of carvedilol, modification π, modification BI and new modification LX in pure form, or in mixtures are formed.
With ethyl acetate containing no water, or quantities of water smaller than 0.8% w/w, preferably 0.6% w/w of water, modification II is isolated in pure crystalline moφhological form.
If we are using ethyl acetate with contents of water between 0.8-1.5% w/w for crystallization of carvedilol, modification IQ in pure form or in mixtures with modification II is formed.
The mixtures of modification HI and new polymoφhic modification LX could be isolated using ethyl acetate with 2-3% w/w of water for re crystallization of carvedilol. The pure new polymoφhic modification LX of carvedilol is prepared using ethyl acetate and water in a miscible mixture as a solvent for crystallization. The miscible mixture of ethyl acetate and water contains preferably more than 3% w/w of water and most preferably more than 4% w/w of water. The preferred concentration of carvedilol is from 8-25% w/w.
The present invention further provides the novel crystalline solid modification of carvedilol, designated as form LX.
The form LX is characterized by the melting point 94.5-96.2°C.
The form LX exhibits IR spectrum, Figure 4, with characteristic absoφtion bands at: 3568.0 cm"1, 3339.1 cm"1, 3287.9 cm"1, 3201.4 cm"1, 3052.8 cm 2976.3 cm"1, 2942.9 cm
2924.3 cm"1, 2896.1 cm"1, 2881.7 cm'1, 2860.0 cm"1, 2841.4 cm"1, 2714.0 cm"1, 2660.6 cm" 1911.7 cm"1, 1882.4 cm"1, 1664.1 cm"1, 1629.7 cm"1, 1607.2 cm"1, 1593.5 cm"1, 1506.9 cm" 1488.0 cm"1, 1470.1 cm"1, 1455.5 cm"1, 1443.8 cm"1, 1406.1 cm"1, 1386.4 cm"1, 1349.9 cm" 1334.9 cm"1, 1307.9 cm"1, 1288.4 cm"1, 1254.0 cm"1, 1227.9 cm"1, 1182.8 cm"1, 1148.4 cm"
1125.4 cm"1, 1104.0 cm"1, 1091.2 cm"1, 1051.7 cm"1, 1018.6 cm'1, 997.2 cm"1, 930.9 cm"1,
906.1 cm"1, 851.5 cm"1, 838.3 cm"1, 816.7 cm"1, 798.3 cm"1, 782.7 cm"1, 771.5 cm"1, 751.9 cm" 748.0 cm"1, 737.1 cm"1, 721.4 cm"1, 657.1 cm"1, 626.6 cm"1, 612.9 cm"1, 586.9 cm"1, 567.9 cm'1, 546.6 cm'1, 526.5 cm"1, 464.2 cm'1, 449.6 cm"1, 435.8 cm"1, 415.8 cm"1.
The most characteristic absoφtion bands of the form LX are at: 3568.0 cm"1, 3339.1 cm"1, 3287.9 cm"1, 2942.9 cm"1, 2896.1 cm"1, 1349.9 cm"1, 1307.9 cm"1, 1288.4 cm"1, 1104.0 cm"1,
997.2 cm"1, 737.1 cm"1.
The form LX is further characterized also by DSC analysis.
The DSC curve of form LX (Figure 5), exhibits the minor endotherm at the peak temperature of about 80°C and the major endotherm at the peak temperature of about 99°C and the onset temperature of about 95°C.
The semi hydrated modification LX releases water from the crystal lattice at temperatures higher than 60°C (the first endotherm exhibits from DSC curve), and there formed non- hydrated modification, which is characterized by the second DSC endotherm. Up to the melting point the non-hydrated material retains the same crystalline lattice. Exposing the non- hydrated modification to the normal ambient environment and temperatures lower than 60°C, reversible hydratation of the anhydrous form occurs and the semi hydrated modification is obtained.
The form LX is also analyzed by XRPD analysis, Figure 6. The X-ray powder diffraction pattern of the form IX shows characteristic two-theta values at: 6.16, 6.46, 8.39, 10.88, 11.39, 12.35, 12.98, 13.62, 14.72, 16.86, 17.42, 18.26, 19.28, 19.58, 21.88, 23.15, 24.61, 25.58, 26.06, 27.40, 27.63, 29.01, 29.55 ± 0.1.
The most characteristic diffractions of the form LX are at 6.16, 6.46, 11.39, 12.35, 13.62, 14.72, 16.86, 19.28, 19.58 and 23.15± 0.1 two-theta degrees.
The following examples illustrate the invention without limiting it thereto.
Examples
Example 1
Preparation of crystalline carvedilol ethyl acetate solvate
20 g of carvedilol moφhological form II was dissolved in 740 ml ethyl acetate with less than 0.1% w/w of water. The mixture was heated to the temperature of the boiling point or till the solid was dissolved, and the clear reaction mixture was obtained. After heating was stopped, the reaction mixture was cooled to approximately 25°C. The solid product started to precipitate from the crystallization mixture. The crystallization mixture was further cooled to 0-5°C and after approximately lhour the solid material was filtered off. The solid material was dried at ambient temperature 20-25°C for 6-12 hours and 16.7 g of ethyl acetate solvate of carvedilol with the melting point from 66-70°C was obtained. According to TGA analysis and 1H NMR the product contained 12-13% w/w of ethyl acetate.
This example was repeated using carvedilol moφhological form HI, a mixture of carvedilol forms II and HI or amoφhous carvedilol instead of carvedilol form II. The products were all identical to the product obtained with carvedilol form II.
Example 2
Preparation of crystalline carvedilol form VH
Carvedilol ethyl acetate solvate was dried at reduced pressure 10-20 mmHg at maximum 50°C to evaporate the solvent and after loss of weight for 12 tol5% in 6-8 hours, non- solvated carvedilol of moφhological form VH with the melting point 68.8-72.4°C was isolated.
Example 3
Preparation of crystalline carvedilol form U
Crystalline carvedilol form II was obtained by drying carvedilol form VII at temperature 70- 80°C for 6-8 hours. Example 4
Preparation of crystalline carvedilol form LX
4 g of carvedilol moφhological form II was dissolved in 26.6 ml ethyl acetate with 4% w/w of water. The mixture was heated to the temperature of the boiling point, or till the solid was dissolved, and the clear reaction mixture was obtained. After heating was stopped, the reaction mixture was cooled to 40-45°C. The solid product started to precipitate from the crystallization mixture, and heating at this temperature was maintained for 0.5-1.5 hour. After the reaction mixture was cooled gradually to 20-25°C and further to 0-5°C. At 0-5°C the crystallization mixture was stirred approximately lhour and the solid material was filtered off. The solid material was dried at ambient temperature 20-25°C for 12 hours. 3.7 g of carvedilol was obtained. The product was dried till constant weight for approximately 2-4 hours at 50- 60°C, at reduced pressure 10-30 mmHg.
3.56g, 91% of product was obtained, with the melting point 94.5-96.2°C.
This example was repeated using carvedilol moφhological form HI, a mixture of carvedilol forms H and HI or amoφhous carvedilol instead of carvedilol form H. The products were all identical to the product obtained with carvedilol form H.
Example 5
Preparation of crystalline carvedilol form LX
5 g of carvedilol moφhological form H was dissolved in 32.1 ml ethyl acetate with 6.8% w/w of water. The mixture was heated to the temperature of the boiling point or till the solid was dissolved and the clear reaction mixture was obtained. After heating was stopped, the reaction mixture was cooled. The product started to precipitate from the crystallization mixture at 25- 30°C. The crystallization mixture was cooled gradually to 0-5°C and after approximately lhour the crystallization mixture was filtered off. The solid material was dried at ambient temperature, 20-25°C for 20 hours. The product was dried till constant weight for approximately 2-4 hours at 50-60°C, and at reduced pressure 10-30 mmHg.
4.74 g, 94.8% of polymoφh LX was obtained, with melting point 94.5-97.3°C. This example was repeated using carvedilol moφhological form HI, a mixture of carvedilol forms H and HI or amoφhous carvedilol instead of carvedilol form H. The products were all identical to the product obtained with carvedilol form H.

Claims

Claims
1. The crystalline carvedilol form LX, characterized by an X-ray powder diffraction pattern having peaks at: 6.16, 6.46, 11.39, 12.35, 13.62, 14.72, 16.86, 19.28, 23.15 ± 0.1 degrees two-theta.
2. The crystalline carvedilol form LX according to claim 1, wherein the X-ray powder diffraction pattern further contains the following two theta values: 6.16, 6.46, 8.39, 10.88, 11.39, 12.35, 12.98, 13.62, 14.72, 16.86, 17.42, 18.26, 19.28, 21.88, 23.15, 24.61, 25.58, 26.06, 27.40, 27.63, 29.01, 29.55 + 0.1
3. The crystalline carvedilol form LX, characterized by the DSC curve which exhibits the minor endotherm at the peak temperature of about 80°C and the major endotherm at the peak temperature of about 99°C and the onset temperature of about 95°C.
4. The crystalline carvedilol form LX, characterized by IR spectrum with characteristic absoφtion bands at: 3568.0 cm"1, 3339.1 cm"1, 3287.9 cm"1, 2942.9 cm"1, 2896.1 cm"1, 1349.9 cm"1, 1307.9 cm"1, 1288.4 cm"1, 1104.0 cm"1, 997.2 cm"1, 737.1 cm"1.
5. A process for the preparation of the crystalline carvedilol form LX, wherein carvedilol is crystallized from ethyl acetate containing more than 3% w/w of water.
6. A process for the preparation of the crystalline carvedilol form LX according to claim 5, wherein ethyl acetate contains preferably more than 4 % w/w of water.
7. A pharmaceutical composition, comprising crystalline carvedilol form LX according to any one of the preceding claims in admixture with at least one pharmaceutically acceptable excipient, diluent, or carrier.
8. A pharmaceutical composition, comprising crystalline carvedilol form LX according to any one of the preceding claims for use as a medicament.
9. The crystalline carvedilol form VH, characterized by an X-ray powder diffraction pattern having peaks at: 6.42, 6.78, 10.94, 11.58, 12.90, 13.62, 16.79, 17.51, 17.90, 20.83 and 27.20 ±0.1 degrees two-theta.
10. The crystalline carvedilol form VH according to claim 9, wherein the X-ray powder diffraction pattern further contains the following two theta values: 6.42, 6.78, 10.94, 11.58, 12.90, 13.62, 16.79, 17.51, 17.90, 18.81, 19.42, 20.83, 21.19, 21.93, 23.30, 24.49, 25.27, 26.09, 27.20, 29.21 ±0.1 degrees two-theta.
11. The crystalline carvedilol form VH, characterized by IR spectrum with peaks at: 3469.2 cm"1, 3278.1 cm"1, 2871.2 cm"1, 1123.6 cm"1, 1095.8 cm"1, 745.0 cm"1, 722.9 cm"1.
12. The crystalline carvedilol form VH, characterized by the DSC curve with the first endotherm at the peak temperature of about 73°C and the second one at the peak temperature of about 114°C.
13. A process for the isolation of the crystalline carvedilol form VH according to claim 9, wherein ethyl acetate solvate is vacuum dried at temperatures lower than 50°C.
14. A process for the preparation of crystalline carvedilol form H, wherein crystalline carvedilol form VH or ethyl acetate solvate is dried at temperatures from 60-100°C.
15. A process for the preparation of crystalline carvedilol form H according to claim 14, wherein the preferred temperature is between 70-80°C.
PCT/SI2004/000029 2003-09-02 2004-09-01 New crystalline forms of carvedilol WO2005021504A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP04775682A EP1660451A2 (en) 2003-09-02 2004-09-01 New crystalline forms of carvedilol

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SI200300218A SI21616A (en) 2003-09-02 2003-09-02 New crystal forms of carvedilol
SIP-200300218 2003-09-02

Publications (2)

Publication Number Publication Date
WO2005021504A2 true WO2005021504A2 (en) 2005-03-10
WO2005021504A3 WO2005021504A3 (en) 2005-06-02

Family

ID=34271325

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/SI2004/000029 WO2005021504A2 (en) 2003-09-02 2004-09-01 New crystalline forms of carvedilol

Country Status (3)

Country Link
EP (1) EP1660451A2 (en)
SI (1) SI21616A (en)
WO (1) WO2005021504A2 (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006135757A1 (en) * 2005-06-09 2006-12-21 Teva Pharmaceutical Industries Ltd. Crystalline forms of carvedilol and processes for their preparation
WO2007043938A1 (en) * 2005-10-07 2007-04-19 Astrazeneca Ab NOVEL CRYSTALLINE FORM OF 3,5-DIBROMO-N- [ (2S) -2- (-4- FLUOROPHENYL) -4- (3-MORPHOLIN-4-YLAZTIDIN-l-YL) BUTYL] -N METHYLBENZAMIDE, MODIFICATION B
US7485663B2 (en) 2000-06-28 2009-02-03 Teva Pharmaceutical Industries Ltd. Carvedilol
US7514467B2 (en) 2002-01-15 2009-04-07 Teva Pharmaceutical Industries Ltd. Crystalline solids of carvedilol and processes for their preparation
US8022094B2 (en) 2006-06-28 2011-09-20 Teva Pharmaceutical Industries Ltd. Carvedilol phosphate

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999005105A1 (en) * 1997-07-22 1999-02-04 Roche Diagnostics Gmbh Thermodynamically stable modification of 1-(4-carbazolyloxy)-3-[2-(2-methoxyphenoxy)ethylamino]-2-propanole, process for its preparation and pharmaceutical compositions containing it
WO2002000216A1 (en) * 2000-06-28 2002-01-03 Teva Pharmaceutical Industries Ltd. Carvedilol
WO2003005970A2 (en) * 2001-07-13 2003-01-23 Smithkline Beecham Corporation Carvedilol polymorph
WO2003029214A1 (en) * 2001-09-28 2003-04-10 F. Hoffmann-La Roche Ag Pseudopolymorphic forms of carvedilol
WO2003059807A2 (en) * 2002-01-15 2003-07-24 Teva Pharmaceutical Industries Ltd. Crystalline solids of carvedilol and processes for their preparation
WO2004041783A1 (en) * 2002-11-08 2004-05-21 Zentiva, A.S. Process for preparation of carvedilol
WO2004041252A1 (en) * 2002-11-08 2004-05-21 Egalet A/S Controlled release carvedilol compositions
WO2004113296A1 (en) * 2003-06-20 2004-12-29 Sun Pharmaceutical Industries Limited A process for preparation of 1-[9h-carbazol-4-yloxy]- 3-[{2-(2-(-(methoxy)phenoxy)-ethyl}-amino]-propan-2-ol

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999005105A1 (en) * 1997-07-22 1999-02-04 Roche Diagnostics Gmbh Thermodynamically stable modification of 1-(4-carbazolyloxy)-3-[2-(2-methoxyphenoxy)ethylamino]-2-propanole, process for its preparation and pharmaceutical compositions containing it
WO2002000216A1 (en) * 2000-06-28 2002-01-03 Teva Pharmaceutical Industries Ltd. Carvedilol
WO2003005970A2 (en) * 2001-07-13 2003-01-23 Smithkline Beecham Corporation Carvedilol polymorph
WO2003029214A1 (en) * 2001-09-28 2003-04-10 F. Hoffmann-La Roche Ag Pseudopolymorphic forms of carvedilol
WO2003059807A2 (en) * 2002-01-15 2003-07-24 Teva Pharmaceutical Industries Ltd. Crystalline solids of carvedilol and processes for their preparation
WO2004041783A1 (en) * 2002-11-08 2004-05-21 Zentiva, A.S. Process for preparation of carvedilol
WO2004041252A1 (en) * 2002-11-08 2004-05-21 Egalet A/S Controlled release carvedilol compositions
WO2004113296A1 (en) * 2003-06-20 2004-12-29 Sun Pharmaceutical Industries Limited A process for preparation of 1-[9h-carbazol-4-yloxy]- 3-[{2-(2-(-(methoxy)phenoxy)-ethyl}-amino]-propan-2-ol

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
VENKATESH, GOPI M. ET AL: "Detection of low levels of the amorphous phase in crystalline pharmaceutical materials by thermally stimulated current spectrometry" PHARMACEUTICAL RESEARCH , 18(1), 98-103 CODEN: PHREEB; ISSN: 0724-8741, 2001, XP002316351 *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7485663B2 (en) 2000-06-28 2009-02-03 Teva Pharmaceutical Industries Ltd. Carvedilol
US7605274B2 (en) 2000-06-28 2009-10-20 Teva Pharmaceutical Industries Ltd Carvedilol
US7514467B2 (en) 2002-01-15 2009-04-07 Teva Pharmaceutical Industries Ltd. Crystalline solids of carvedilol and processes for their preparation
US7598396B2 (en) 2002-01-15 2009-10-06 Teva Pharmaceutical Industries Ltd Crystalline solids of carvedilol and processes for their preparation
WO2006135757A1 (en) * 2005-06-09 2006-12-21 Teva Pharmaceutical Industries Ltd. Crystalline forms of carvedilol and processes for their preparation
WO2007043938A1 (en) * 2005-10-07 2007-04-19 Astrazeneca Ab NOVEL CRYSTALLINE FORM OF 3,5-DIBROMO-N- [ (2S) -2- (-4- FLUOROPHENYL) -4- (3-MORPHOLIN-4-YLAZTIDIN-l-YL) BUTYL] -N METHYLBENZAMIDE, MODIFICATION B
US8022094B2 (en) 2006-06-28 2011-09-20 Teva Pharmaceutical Industries Ltd. Carvedilol phosphate
US8114900B2 (en) 2006-06-28 2012-02-14 Teva Pharmaceutical Industries Ltd. Amorphous carvedilol dihydrogen phosphate
US8124644B2 (en) 2006-06-28 2012-02-28 Teva Pharmaceutical Industries Ltd. Carvedilol phosphate

Also Published As

Publication number Publication date
SI21616A (en) 2005-04-30
EP1660451A2 (en) 2006-05-31
WO2005021504A3 (en) 2005-06-02

Similar Documents

Publication Publication Date Title
US8853405B2 (en) Crystalline forms of pitavastatin calcium
US6600073B1 (en) Methods for preparation of sertraline hydrochloride polymorphs
EP2409967A1 (en) Polymorphs of n-hydroxy-3-[4-[[[2-(2-methyl-1h-indol-3-yl)ethyl]amino]methyl]phenyl]-2e-2-propenamide
US20080070949A1 (en) Polymorphs of rimonabant
WO2008084494A1 (en) Novel polymorphic forms of carvedilol dihydrogen phosphate and process for preparing the same
MXPA03003459A (en) Crystalline venlafaxine base and novel polymorphs of venlafaxine hydrochloride, processes for preparing thereof.
EP2468762A1 (en) Optimized synthesis of pure, non-polymorphic, crystalline bile acids with defined particle size
EP2780327A1 (en) Polymorphic forms of ivabradine hydrochloride
EP1133459B1 (en) Sertraline hydrochloride form v
EP2601175A1 (en) A novel crystalline compound comprising saxagliptin and phosphoric acid
EP3564224A2 (en) Crystalline form of vortioxetine hydrobromide as antidepressant drug
EP1660451A2 (en) New crystalline forms of carvedilol
US20050113309A1 (en) Crystalline forms(2s)-n-5[amino(imino)methyl]-2-thienylmethyl-1-(2r)-2[(carboxymethyl) amino]-3,3-diphenylpropanoyl-2-pyrrolidinecarboxamide nh2o
EP2159225A1 (en) Gemifloxacin process and polymorphs
EP4232435A1 (en) Processes for the preparation of ivabradine hcl polymorphs
WO2022264072A1 (en) Polymorphs of 2-(3,5-dichlorophenyl)-l,3-benzoxazole-6-carboxylic acid
EP1632473A1 (en) Sertraline hydrochloride polymorphs
SI21233A (en) High purity crystalline hydrate forms of amlodipine benzensulphonate, methods of their preparation and usage
ZA200404332B (en) A novel polymorph of sertraline hydrochloride and composition containing thereof, novel methods for preparation of sertraline hydrochloride polymorphs and amorphous form.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2004775682

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2004775682

Country of ref document: EP